{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:35:33Z","timestamp":1761708933241,"version":"3.40.2"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The current clinical approach for treating autoimmune diseases is to broadly blunt immune responses as a means of preventing autoimmune pathology. Among the major side effects of this strategy are depressed beneficial immunity and increased rates of infections and tumors. Using the experimental autoimmune encephalomyelitis model for human multiple sclerosis, we report a novel alternative approach for purging autoreactive T cells that spares beneficial immunity. The moderate and temporally limited use of etoposide, a topoisomerase inhibitor, to eliminate encephalitogenic T cells significantly reduces the onset and severity of experimental autoimmune encephalomyelitis, dampens cytokine production and overall pathology, while dramatically limiting the off-target effects on naive and memory adaptive immunity. Etoposide-treated mice show no or significantly ameliorated pathology with reduced antigenic spread, yet have normal T cell and T-dependent B cell responses to de novo antigenic challenges as well as unimpaired memory T cell responses to viral rechallenge. Thus, etoposide therapy can selectively ablate effector T cells and limit pathology in an animal model of autoimmunity while sparing protective immune responses. This strategy could lead to novel approaches for the treatment of autoimmune diseases with both enhanced efficacy and decreased treatment-associated morbidities.<\/jats:p>","DOI":"10.4049\/jimmunol.1301891","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T05:13:21Z","timestamp":1385442801000},"page":"73-83","source":"Crossref","is-referenced-by-count":13,"title":["Eliminating Encephalitogenic T Cells without Undermining Protective Immunity"],"prefix":"10.1093","volume":"192","author":[{"given":"Jonathan P","family":"McNally","sequence":"first","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen E","family":"Elfers","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine E","family":"Terrell","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Grunblatt","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Hildeman","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B","family":"Jordan","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"},{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D","family":"Katz","sequence":"additional","affiliation":[{"name":"Division of Immunobiology, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"},{"name":"Division of Endocrinology, Diabetes Research Center, Cincinnati Children\u2019s Research Foundation , Cincinnati, OH 45229"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH 45229"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,1]]},"reference":[{"key":"2025032404061206600_r1","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/1352458508095004","article-title":"Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"14","author":"Prakash","year":"2008","journal-title":"Mult. Scler."},{"key":"2025032404061206600_r2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"2025032404061206600_r3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis\u2014the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2025032404061206600_r4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.21800","article-title":"Multiple sclerosis: distribution of inflammatory cells in newly forming lesions","volume":"66","author":"Henderson","year":"2009","journal-title":"Ann. Neurol."},{"key":"2025032404061206600_r5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon \u03b2-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"key":"2025032404061206600_r6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2025032404061206600_r7","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/01.wco.0000413319.87092.19","article-title":"Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs","volume":"25","author":"Miller","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"2025032404061206600_r8","doi-asserted-by":"crossref","first-page":"47408","DOI":"10.1074\/jbc.M307687200","article-title":"Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases","volume":"278","author":"Billich","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2025032404061206600_r9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14737175.8.5.699","article-title":"FTY720 (fingolimod) for relapsing multiple sclerosis","volume":"8","author":"Horga","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"2025032404061206600_r10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis\u202f: a placebo- controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"2025032404061206600_r11","first-page":"CD002127","article-title":"Mitoxantrone for multiple sclerosis","volume":"5","author":"Martinelli Boneschi","year":"2013","journal-title":"CochraneDatabase Syst. Rev."},{"key":"2025032404061206600_r12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025032404061206600_r13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2025032404061206600_r14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMc0706103","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis","volume":"358","author":"Mullen","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2025032404061206600_r15","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.4049\/jimmunol.181.7.4648","article-title":"Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis","volume":"181","author":"Furtado","year":"2008","journal-title":"J. Immunol."},{"key":"2025032404061206600_r16","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.4049\/jimmunol.1100713","article-title":"Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells","volume":"187","author":"Penaranda","year":"2011","journal-title":"J. Immunol."},{"key":"2025032404061206600_r17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/intimm\/dxg076","article-title":"Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo","volume":"15","author":"Zocher","year":"2003","journal-title":"Int. Immunol."},{"key":"2025032404061206600_r18","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/brain\/awl075","article-title":"Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research","volume":"129","author":"Gold","year":"2006","journal-title":"Brain"},{"key":"2025032404061206600_r19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/eji.1830110409","article-title":"Genetic control of autoimmune encephalomyelitis and recognition of the critical nonapeptide moiety of myelin basic protein in guinea pigs are exerted through interaction of lymphocytes and macrophages","volume":"11","author":"Ben-Nun","year":"1981","journal-title":"Eur. J. Immunol."},{"key":"2025032404061206600_r20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF00253972","article-title":"Etoposide-induced DNA cleavage in human leukemia cells","volume":"20","author":"Edwards","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2025032404061206600_r21","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/jnci\/80.19.1526","article-title":"Mechanism of action of antitumor drug etoposide: a review","volume":"80","author":"van Maanen","year":"1988","journal-title":"J. Natl. Cancer Inst."},{"key":"2025032404061206600_r22","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"2025032404061206600_r23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2013","journal-title":"J. Immunol."},{"key":"2025032404061206600_r24","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1128\/MCB.21.10.3604-3608.2001","article-title":"Characterization of XIAP-deficient mice","volume":"21","author":"Harlin","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"2025032404061206600_r25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1099800406290932","article-title":"The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms","volume":"8","author":"Wood","year":"2006","journal-title":"Biol. Res. Nurs."},{"key":"2025032404061206600_r26","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/eji.200635897","article-title":"Bim mediates apoptosis of CD127lo effector T cells and limits T cell memory","volume":"36","author":"Wojciechowski","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"2025032404061206600_r27","doi-asserted-by":"crossref","first-page":"9672","DOI":"10.1128\/jvi.71.12.9672-9678.1997","article-title":"Vaccination against persistent viral infection immunopathological disease","volume":"71","author":"Hildeman","year":"1997","journal-title":"J. Virol."},{"key":"2025032404061206600_r28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1172\/JCI25575","article-title":"IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc\u03b3RIIb cross-linking","volume":"116","author":"Strait","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2025032404061206600_r29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/eji.1830250419","article-title":"Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL\/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes","volume":"25","author":"Kerlero de Rosbo","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"2025032404061206600_r30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"2025032404061206600_r31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"2025032404061206600_r32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"key":"2025032404061206600_r33","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","article-title":"Etoposide: four decades of development of a topoisomerase II inhibitor","volume":"34","author":"Hande","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"2025032404061206600_r34","first-page":"278","article-title":"Relapsing experimental allergic encephalomyelitis in the SJL\/J mouse","volume":"45","author":"Brown","year":"1981","journal-title":"Lab. Invest."},{"key":"2025032404061206600_r35","first-page":"347","article-title":"Epitope spreading: a mechanism for progression of autoimmune disease","volume":"48","author":"Tuohy","year":"2000","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"2025032404061206600_r36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nm1202","article-title":"Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis","volume":"11","author":"McMahon","year":"2005","journal-title":"Nat. Med."},{"key":"2025032404061206600_r37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"2025032404061206600_r38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1745-7580-6-4","article-title":"Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage","volume":"6","author":"Kotturi","year":"2010","journal-title":"Immunome Res."},{"key":"2025032404061206600_r39","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/362758a0","article-title":"Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells","volume":"362","author":"Moskophidis","year":"1993","journal-title":"Nature"},{"key":"2025032404061206600_r40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jneuroim.2008.06.030","article-title":"Increased X-linked inhibitor of apoptosis protein (XIAP) expression exacerbates experimental autoimmune encephalomyelitis (EAE)","volume":"203","author":"Moore","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"2025032404061206600_r41","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1084\/jem.20070618","article-title":"Bim\/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis","volume":"204","author":"Wojciechowski","year":"2007","journal-title":"J. Exp. Med."},{"key":"2025032404061206600_r42","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.1128\/JVI.00855-06","article-title":"Role of Bim in regulating CD8+ T-cell responses during chronic viral infection","volume":"80","author":"Grayson","year":"2006","journal-title":"J. Virol."},{"key":"2025032404061206600_r43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2353\/ajpath.2008.080142","article-title":"Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis","volume":"173","author":"Elyaman","year":"2008","journal-title":"Am. J. Pathol."},{"key":"2025032404061206600_r44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2007.10.022","article-title":"Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes","volume":"193","author":"Moore","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"2025032404061206600_r45","doi-asserted-by":"crossref","first-page":"26776","DOI":"10.1074\/jbc.M505203200","article-title":"A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells","volume":"280","author":"Arva","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2025032404061206600_r46","doi-asserted-by":"crossref","first-page":"e17574","DOI":"10.1371\/journal.pone.0017574","article-title":"Role of p53 serine 46 in p53 target gene regulation","volume":"6","author":"Smeenk","year":"2011","journal-title":"PLoS One"},{"key":"2025032404061206600_r47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1476-4598-9-164","article-title":"Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1","volume":"9","author":"Zall","year":"2010","journal-title":"Mol. Cancer"},{"key":"2025032404061206600_r48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.scr.2007.10.003","article-title":"p53 is required for etoposide-induced apoptosis of human embryonic stem cells","volume":"1","author":"Grandela","year":"2007","journal-title":"Stem Cell Res."},{"key":"2025032404061206600_r49","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1182\/blood-2013-04-495309","article-title":"Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8+ T cells and dendritic cells","volume":"121","author":"Terrell","year":"2013","journal-title":"Blood"},{"key":"2025032404061206600_r50","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1002\/jcb.23263","article-title":"Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes","volume":"112","author":"Ku\u017eelov\u00e1","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"2025032404061206600_r51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nchembio.83","article-title":"Identification of RIP1 kinase as a specific cellular target of necrostatins","volume":"4","author":"Degterev","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"2025032404061206600_r52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archneurol.2009.16","article-title":"Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis","volume":"66","author":"Oh","year":"2009","journal-title":"Arch. Neurol."},{"key":"2025032404061206600_r53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pbc.21082","article-title":"Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis","volume":"48","author":"Imashuku","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"key":"2025032404061206600_r54","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"2025032404061206600_r55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.21567","article-title":"Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy","volume":"218","author":"Azmi","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"2025032404061206600_r56","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.4049\/jimmunol.0802813","article-title":"The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity","volume":"182","author":"Bardwell","year":"2009","journal-title":"J. Immunol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/192\/1\/73\/62509194\/1301891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/192\/1\/73\/62509194\/1301891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T04:30:02Z","timestamp":1742790602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/192\/1\/73\/7993503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1301891","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"type":"print","value":"0022-1767"},{"type":"electronic","value":"1550-6606"}],"subject":[],"published-other":{"date-parts":[[2014,1]]},"published":{"date-parts":[[2014,1,1]]}}}